Pfizer Inc. (PFE)

Name: Pfizer Inc. (PFE): results, filings decoded, planned insider sales, 13F holders, insiders, Congress and short interest
Creator: GreekSoup
License: https://creativecommons.org/licenses/by/4.0/

Compare with another name

Pfizer Inc. (PFE) reported revenue of $15.0 billion for Q2 FY2026, the quarter ended 28 June 2026, up 2.6% on the same quarter a year earlier. Net income was -$248 million, and diluted earnings per share $-0.04. The figures are the company's own, from the 10-Q it filed with the SEC on 4 August 2026.

Revenue$15.0 billionup 2.6%

Net income-$248 million

Diluted EPS$-0.04

QuarterQ2 FY2026ended 28 June 2026

Ratios

From the filings

ROE5.1%

ROCEn/a

Operating marginn/a

Net margin6.8%

FCF margin17.2%

Interest covern/a

Debt to equity0.71

Cash conversion3.09

Share count, 1 year0.2%

Sales CAGR, 3 years-14.8%

Profit CAGR, 3 years-37.2%

EPS, TTM$0.76

At the close of 21 September 2026

Price$27.74

Market cap$158.1 billion

Stock P/E36.50

Price to book1.86

EV / EBITDAn/a

Dividend yield6.2%

Market cap / sales2.48

52-week high$29.02

52-week low$23.60

Price, 1 year15.4%

Price CAGR, 3 years-5.3%

Price CAGR, 5 years-8.8%

Every figure is arithmetic on the filed lines (hover a name for the formula); the priced ones use the latest daily close, CBOE delayed quotes, daily history, by CBOE, for splits. Debt to equity here stands on long-term debt as Pfizer Inc. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.

Price, 17 September 2021 to 21 September 2026

Show

50-day average 200-day average Volume

Daily closes from CBOE delayed quotes, daily history, by CBOE, for splits; the last is 21 September 2026. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on PFE

Filings	20 in twelve months: 10 current reports (8-K), about 4 results of operations; 2 regulation fd disclosure; 2 other events; 1 officer or director change; 1 shareholder vote
Planned insider sales	no Form 144 notice in twelve months
Options tape	put/call 0.59 by open interest on 23 September 2026; the straddle prices a 1.6% move to 25 September 2026
Holders	11 of the followed funds hold it; largest Geode Capital Management; 2 Schedule 13D or 13G filings in twelve months
Insider trading	2 sales and 3 purchases on Form 4 in twelve months
Congress	3 House trades disclosed in six months
Short interest	151.5 million shares short, 4.33 days to cover at 31 August 2026
Documents	the 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Quarterly results, the last 12 quarters

	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026
Revenue	13,232	14,248	14,879	13,283	17,702	17,763	13,715	14,653	16,654	17,557	14,451	15,034
Cost of revenue	9,269	7,562	3,379	3,300	5,263	5,909	2,845	3,778	4,172	5,272	3,548	4,092
Gross profit	3,963	6,686	11,500	9,983	12,439	11,854	10,870	10,875	12,482	12,285	10,903	10,942
Gross margin	30%	47%	77%	75%	70%	67%	79%	74%	75%	70%	75%	73%
R&D	2,711	2,815	2,493	2,696	2,598	3,035	2,203	2,482	2,546	3,206	2,490	2,809
SG&A	3,281	4,575	3,495	3,717	3,244	4,274	3,031	3,415	3,186	4,162	2,961	3,411
Interest expense	695	688	790	778	783	740	654	654	652	711	668	667
Pre-tax income	-3,352	-4,129	3,421	-103	4,715	-10.0	2,785	3,044	3,334	-1,643	3,170	-653
Tax rate	n/a	n/a	9%	n/a	5%	n/a	-7%	5%	-6%	n/a	15%	n/a
Net income	-2,382	-3,369	3,115	41.0	4,465	410	2,967	2,910	3,541	-1,647	2,687	-248
Net margin	-18%	-24%	21%	0%	25%	2%	22%	20%	21%	-9%	19%	-2%
Diluted EPS	-$0.42	-$0.59	$0.55	$0.01	$0.78	$0.07	$0.52	$0.51	$0.62	-$0.29	$0.47	-$0.04
Operating cash flow	3,456	5,240	1,090	-1,781	6,714	6,721	2,335	-582	4,603	5,348	2,615	835
Capital expenditure	810	1,044	704	637	651	917	564	618	602	845	436	533
Free cash flow	2,646	4,196	386	-2,418	6,063	5,804	1,771	-1,200	4,001	4,503	2,179	302
Buybacks	0.0	0.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Shares outstanding	5,646m	5,647m	5,667m	5,667m	5,667m	5,667m	5,685m	5,686m	5,686m	5,686m	5,699m	5,700m
Filing	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Profit and loss, 12 fiscal years and the trailing twelve months

	FY2012 †	FY2013 †	FY2016 †	FY2017 †	FY2018 †	FY2019 †	FY2020 †	FY2021 †	FY2022 †	FY2023 †	FY2024	FY2025	TTM
Revenue	54,657	51,584	52,824	52,546	40,825	40,905	41,651	81,288	101,175	59,553	63,627	62,579	63,696
Cost of revenue	9,821	9,586	12,322	11,228	8,987	8,054	8,484	30,821	34,344	24,954	17,851	16,067	17,084
Gross profit	47,652	41,998	40,502	41,318	42,399	41,531	32,959	50,467	65,986	33,542	45,776	46,512	46,612
Gross margin	87.2%	81.4%	76.7%	78.6%	103.9%	101.5%	79.1%	62.1%	65.2%	56.3%	71.9%	74.3%	73.2%
Research and development	7,482	6,678	7,892	7,683	7,760	8,385	8,709	10,360	11,428	10,679	10,822	10,437	11,051
Selling, general and administrative	15,171	14,355	14,837	14,784	12,612	12,726	11,615	12,703	13,677	14,771	14,730	13,794	13,720
Interest expense	1,524	1,414	1,186	1,270	1,316	1,574	1,449	1,291	1,238	2,209	3,091	2,671	2,698
Pre-tax income	11,242	15,716	8,351	12,305	3,594	11,321	7,036	24,311	34,729	1,058	8,023	7,520	4,208
Income tax	2,221	4,306	1,123	-9,049	-266	583	370	1,852	3,328	-1,115	-28.0	-266	-164
Effective tax rate	19.8%	27.4%	13.4%	-73.5%	-7.4%	5.1%	5.3%	7.6%	9.6%	-105.4%	-0.3%	-3.5%	-3.9%
Net income	14,570	22,003	7,215	21,308	11,153	16,026	9,159	21,979	31,372	2,119	8,031	7,771	4,333
Net margin	26.7%	42.7%	13.7%	40.6%	27.3%	39.2%	22.0%	27.0%	31.0%	3.6%	12.6%	12.4%	6.8%
Diluted EPS	$1.94	$3.19	$1.17	$3.52	$1.87	$2.87	$1.71	$3.85	$5.47	$0.37	$1.41	$1.36	$0.76
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Income statement lines from each year's 10-K, the year linked to its filing; TTM is the sum of the last four quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

	FY2012 †	FY2013 †	FY2016 †	FY2017 †	FY2018 †	FY2019 †	FY2020 †	FY2021 †	FY2022 †	FY2023 †	FY2024	FY2025	TTM
Operating cash flow	16,746	17,684	16,192	16,802	15,827	12,588	14,403	32,580	29,267	8,700	12,744	11,704	13,401
Capital expenditure	1,327	1,206	1,823	1,956	1,984	2,046	2,226	2,711	3,236	3,907	2,909	2,629	2,416
Free cash flow	15,419	16,478	14,369	14,846	13,843	10,542	12,177	29,869	26,031	4,793	9,835	9,075	10,985
Free cash flow margin	28.2%	31.9%	27.2%	28.3%	33.9%	25.8%	29.2%	36.7%	25.7%	8.0%	15.5%	14.5%	17.2%
Depreciation and amortisation	7,394	6,306	5,757	6,269	6,384	5,755	4,681	5,191	5,064	6,290	7,013	6,592	6,584
Share-based compensation	481	523	691	840	923	687	756	1,182	872	525	877	799	947
Buybacks	8,228	16,290	5,000	5,000	12,198	8,865	0.0	0.0	2,000	0.0	0.0	n/a	n/a
Dividend per share	$0.88	$0.96	$1.22	$1.30	$1.38	$1.46	$1.53	$1.57	$1.61	$1.65	$1.69	$1.72	n/a
Diluted shares, weighted	7,508m	6,895m	6,159m	6,058m	5,977m	5,675m	5,632m	5,708m	5,733m	5,709m	5,700m	5,713m	5,699m
Shares outstanding at period end	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	5,700m
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Buybacks and dividends are the cash paid in the year, from the cash flow statement; the dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet at year end

	FY2012 †	FY2013 †	FY2016 †	FY2017 †	FY2018 †	FY2019 †	FY2020 †	FY2021 †	FY2022 †	FY2023 †	FY2024	FY2025	TTM
Total assets	185,798	172,101	171,615	171,797	159,422	167,489	154,229	181,476	197,205	226,501	213,396	208,160	201,131
Cash and equivalents	10,081	2,183	2,595	1,342	1,139	1,121	1,784	1,944	416	2,853	1,043	1,142	976
Receivables	10,675	9,357	8,225	8,221	8,025	6,772	7,913	11,479	10,952	11,566	11,463	11,874	12,490
Inventory	6,076	6,166	6,783	7,578	7,508	7,068	8,020	9,059	8,981	10,189	10,851	10,654	9,945
Goodwill	43,661	42,519	54,449	55,952	42,927	48,181	49,577	49,208	51,375	67,783	68,527	71,264	71,419
Long-term debt	31,036	30,462	31,398	33,538	32,909	35,955	4,000	36,195	32,884	61,538	57,405	61,641	60,495
Operating lease liabilities	n/a	n/a	n/a	n/a	n/a	1,030	1,108	2,510	2,597	2,626	2,286	2,291	n/a
Shareholders' equity	81,260	76,307	59,544	71,308	63,407	63,143	63,238	77,201	95,661	89,014	88,203	86,476	85,190
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

At the fiscal year end; the TTM column is the latest quarter end. A line the company does not tag under the usual name is left out.

Compounded growth

	10 years	5 years	3 years	TTM
Sales growth, compounded	n/a	8.5%	-14.8%	-0.2%
Profit growth, compounded	n/a	-3.2%	-37.2%	-59.7%
Return on equity, average	18.1%	16.3%	6.8%	9.0%

Compounded growth is the latest fiscal year over the year that many years earlier, annualised; the TTM column is the last four quarters over the four before. Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Peers: Pharmaceutical Preparations

Company	Market cap	P/E	ROE	Op. margin	Sales growth TTM	Debt to equity	Div. yield
Eli Lilly & Co. LLY	$1.10 trillion	39.09	78.8%	n/a	49.6%	1.41	0.5%
Johnson & Johnson JNJ	$649.4 billion	31.30	24.8%	n/a	8.1%	0.44	1.9%
ABBVIE Inc. ABBV	$467.4 billion	74.71	n/a	26.2%	10.4%	n/a	2.6%
Merck & Co., Inc. MRK	$368.8 billion	119.60	7.6%	n/a	4.6%	1.29	2.2%
Abbott Laboratories ABT	$179.4 billion	28.85	12.1%	17.1%	6.6%	0.57	2.3%
Pfizer Inc. PFE	$158.1 billion	36.50	5.1%	n/a	-0.2%	0.71	6.2%
Vertex Pharmaceuticals Inc. / MA VRTX	$129.4 billion	29.74	21.8%	38.0%	10.2%	0.00	n/a
Bristol-Myers Squibb Co. BMY	$127.9 billion	13.76	41.6%	24.2%	3.1%	1.92	4.0%
Regeneron Pharmaceuticals, Inc. REGN	$84.6 billion	19.77	13.7%	24.7%	9.3%	0.06	0.5%
Zoetis Inc. ZTS	$29.5 billion	11.75	83.1%	n/a	1.4%	2.87	2.8%
Viatris Inc. VTRS	$19.6 billion	n/a	-2.9%	-0.6%	4.4%	0.81	2.8%

The names on this site in the same industry (the SEC's SIC description), by market capitalisation. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close.

Filings

Filing	Period	Filed	Where
10-Q	28 June 2026	4 August 2026	EDGAR
10-Q	29 March 2026	5 May 2026	EDGAR
10-K	31 December 2025	26 February 2026	EDGAR
10-Q	28 September 2025	4 November 2025	EDGAR
10-Q	29 June 2025	5 August 2025	EDGAR
10-Q	30 March 2025	5 May 2025	EDGAR
10-K	31 December 2024	27 February 2025	EDGAR
10-Q	29 September 2024	4 November 2024	EDGAR
10-Q	30 June 2024	5 August 2024	EDGAR
10-Q	31 March 2024	8 May 2024	EDGAR

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install